Shares of Cytori Therapeutics Inc. (NASDAQ:CYTX) fell to a one-year low of $1.46 Wednesday morning after the company disclosed late Tuesday that it placed a clinical hold on enrollment in the phase II ATHENA and ATHENA II trials of its adipose-derived regenerative cells (ADRCs) in heart failure patients. Read More
LONDON – The ability to boost the efficiency of bone marrow transplantations – and possibly allow bone marrow and cord-blood transplantation in people who previously would not have been considered suitable candidates – could follow from a new understanding of how to stimulate hematopoietic stem cells. Read More
Auris Medical Holding AG netted $51 million in a bargain basement initial public offering (IPO), comprising 9.4 million shares priced at $6 per share. Gross proceeds were $56.4 million, whereas the Zug, Switzerland-based firm originally planned to raise as much as $82.8 million, by offering 6.9 million shares, priced at $10 to $12 per share. Read More
SHANGHAI – Sotio AS, of Prague, has expanded its China footprint with the opening of a GMP, clean-room lab for the production of active cellular immunotherapy treatments against cancer diseases. This is their second facility, giving them a combined lab space of 1,000 square meters in Beijing. Sotio will produce therapeutic cellular treatments for patients with prostate and lung cancer. Read More
Enumeral Biomedical Holdings Inc., an early stage immunomodulator discovery and development venture, has transitioned to the OTCQB through a reverse merger with a shell company simultaneous with the close of a $21.5 million equity financing. Read More
Alder Biopharmaceuticals Inc. and Eli Lilly and Co. stand as the only developers of calcitonin gene-related peptide (CGRP) blockers that have generated human efficacy data in migraine patients, but Amgen Inc. and Teva Pharmaceuticals Ltd. are courting similar phase II success in the clinic. Read More
Jazz Pharmaceuticals plc, of Dublin, reported total revenues for their second quarter ended June 30, 2014, were $291.2 million, an increase of 40 percent over total revenues of $208.3 million for the second quarter of 2013. Read More
Avalanche Biotechnologies Inc., of Menlo Park, Calif., said it closed its initial public offering (IPO) of 6,900,000 shares of its common stock at $17 each, which included the exercise in full by the underwriters of their option to purchase up to 900,000 additional shares of common stock. Read More
Celgene Corp., of Summit, N.J., said Health Canada approved Abraxane for injectable suspension (nab-paclitaxel powder for injectable suspension) in combination with gemcitabine as first-line treatment for adults with metastatic pancreatic cancer, based on the results of the phase III MPACT (Metastatic Pancreatic Adenocarcinoma Clinical Trial) study of 861 chemotherapy-naïve patients with metastatic pancreatic cancer from 11 countries, including Canada. Read More
Cara Therapeutics Inc., of Shelton, Conn., disclosed the dosing of the first dialysis patients in a phase II trial of an intravenous formulation of its peripherally selective kappa opioid agonist, CR845, for the treatment of uremic pruritus. The company expects to report top-line data from this trial in the first half of 2015. Read More
Yabao Pharmaceutical Co. Inc., of Beijing, signed a strategic partnership with Changzhou Le Sun Pharmaceuticals Ltd., of Changzhou, China, to co-develop Le Sun's leading PLK/PI3K dual inhibitor LS-008, which currently is in preclinical development. Read More